Clinical trial
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
NCT00410761 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00410761 |
|---|---|
| Title | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer |
| Official title | An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Thyroid Cancer |
| Intervention type | Drug |
| Interventions | ZD6474 (Vandetanib) |
| Enrollment | 331 |
| Start date | Nov 23, 2006 |
| Primary completion | Jul 31, 2009 |
| Completion | Jul 26, 2024 |
| First posted | Dec 13, 2006 |
| Last update posted | Sep 24, 2025 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy and 12 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: